256
Views
9
CrossRef citations to date
0
Altmetric
Original Article: Research

An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing

, , , , , , & show all
Pages 1161-1167 | Received 16 Jan 2008, Accepted 07 Mar 2008, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Mohamad Farid, Ying Wei Yau, Kevin Tay, Richard Quek, Miriam Tao, Ghee Chong Koo, Susan Loong & Soon Thye Lim. (2011) A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma. Acta Oncologica 50:4, pages 589-590.
Read now

Articles from other publishers (8)

Yali Wang, Wenbo Zhou, Jianfeng Chen, Jinghong Chen, Peng Deng, Huang Chen, Yichen Sun, Zhaoliang Yu, Diwen Pang, Lizhen Liu, Peili Wang, Jing Han Hong, Bin Tean Teh, Huiqiang Huang, Wenyu Li, Zhengfang Yi, Soon Thye Lim, Yihua Chen, Choon Kiat Ong, Mingyao Liu & Jing Tan. (2023) Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T‐cell lymphoma. MedComm 4:4.
Crossref
Nurulhuda Mustafa, Adina Huey Fang Nee, Jing Yuan Chooi, Sabrina Hui Min Toh, Tae-Hoon Chung, Viknesvaran Selvarajan, Shuangyi Fan, Siok Bian Ng, Michelle Poon, Esther Chan, Joanne Lee, Yen Lin Chee, Anand D Jeyasekharan, Longen Zhou, Jennifer Yang & Wee Joo Chng. (2021) Determinants of response to daratumumab in Epstein-Barr virus-positive natural killer and T-cell lymphoma. Journal for ImmunoTherapy of Cancer 9:7, pages e002123.
Crossref
Tammy Linlin Song, Maarja-Liisa Nairismägi, Yurike Laurensia, Jing-Quan Lim, Jing TanZhi-Mei LiWan-Lu Pang, Atish KizhakeyilGiovani-Claresta WijayaDa-Chuan HuangSanjanaa NagarajanBurton Kuan-Hui Chia, Daryl Cheah, Yan-Hui LiuFen ZhangHui-Lan RaoTiffany Tang, Esther Kam-Yin Wong, Jin-Xin BeiJabed Iqbal, Nicholas-Francis GrigoropoulosSiok-Bian Ng, Wee-Joo Chng, Bin-Tean TehSoo-Yong Tan, Navin Kumar Verma, Hao Fan, Soon-Thye Lim & Choon-Kiat Ong. (2018) Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood 132:11, pages 1146-1158.
Crossref
Yan Ting Hee, Junli Yan, Dean Nizetic & Wee-Joo Chng. (2018) LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL). Oncotarget 9:61, pages 31832-31841.
Crossref
M. -L. Nairismägi, M. E. Gerritsen, Z. M. Li, G. C. Wijaya, B. K. H. Chia, Y. Laurensia, J. Q. Lim, K. W. Yeoh, X. S. Yao, W. L. Pang, A. Bisconte, R. J. Hill, J. M. Bradshaw, D. Huang, T. L. L. Song, C. C. Y. Ng, V. Rajasegaran, T. Tang, Q. Q. Tang, X. J. Xia, T. B. Kang, B. T. Teh, S. T. Lim, C. K. Ong & J. Tan. (2018) Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma. Leukemia 32:5, pages 1147-1156.
Crossref
Jun-ichi Kawada, Yoshinori Ito, Seiko Iwata, Michio Suzuki, Yoshihiko Kawano, Tetsuhiro Kanazawa, Mohammed Nure Alam Siddiquey & Hiroshi Kimura. (2014) mTOR Inhibitors Induce Cell-Cycle Arrest and Inhibit Tumor Growth in Epstein–Barr Virus–Associated T and Natural Killer Cell Lymphoma Cells. Clinical Cancer Research 20:21, pages 5412-5422.
Crossref
Yenlin Huang, Laurence de Leval & Philippe Gaulard. (2013) Molecular underpinning of extranodal NK/T-cell lymphoma. Best Practice & Research Clinical Haematology 26:1, pages 57-74.
Crossref
Ghee Chong Koo, Soo Yong Tan, Tiffany Tang, Song Ling Poon, George E. Allen, Leonard Tan, Soo Ching Chong, Whee Sze Ong, Kevin Tay, Miriam Tao, Richard Quek, Susan Loong, Kheng-Wei Yeoh, Swee Peng Yap, Kuo Ann Lee, Lay Cheng Lim, Daryl Tan, Christopher Goh, Ioana Cutcutache, Willie Yu, Cedric Chuan Young Ng, Vikneswari Rajasegaran, Hong Lee Heng, Anna Gan, Choon Kiat Ong, Steve Rozen, Patrick Tan, Bin Tean Teh & Soon Thye Lim. (2012) Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discovery 2:7, pages 591-597.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.